Global Blood Therapeutics, Inc. (GBT) VP Peter Radovich Sells 12,500 Shares
Global Blood Therapeutics, Inc. (NASDAQ:GBT) VP Peter Radovich sold 12,500 shares of Global Blood Therapeutics stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $35.00, for a total value of $437,500.00. Following the completion of the sale, the vice president now directly owns 2,684 shares in the company, valued at approximately $93,940. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Global Blood Therapeutics, Inc. (GBT) traded up 2.98% on Tuesday, reaching $39.80. The company’s stock had a trading volume of 1,650,257 shares. The company’s market cap is $1.74 billion. Global Blood Therapeutics, Inc. has a 52-week low of $13.35 and a 52-week high of $41.15. The firm’s 50-day moving average price is $31.21 and its 200 day moving average price is $29.36.
Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.06. During the same period in the previous year, the company earned ($0.58) earnings per share. Equities analysts anticipate that Global Blood Therapeutics, Inc. will post ($2.44) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/31/global-blood-therapeutics-inc-gbt-vp-peter-radovich-sells-12500-shares.html.
A number of equities research analysts recently issued reports on the company. Oppenheimer Holdings, Inc. set a $53.00 target price on Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday, October 23rd. BidaskClub raised Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Wedbush reissued an “ourperform” rating and issued a $73.00 target price on shares of Global Blood Therapeutics in a research report on Monday, September 18th. Cowen and Company reissued an “outperform” rating and issued a $83.00 target price on shares of Global Blood Therapeutics in a research report on Monday, August 14th. Finally, Needham & Company LLC assumed coverage on Global Blood Therapeutics in a research report on Wednesday, September 20th. They issued a “buy” rating and a $51.00 target price on the stock. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $54.08.
Several institutional investors have recently modified their holdings of GBT. BlackRock Inc. raised its stake in shares of Global Blood Therapeutics by 4,675.5% in the first quarter. BlackRock Inc. now owns 2,618,847 shares of the company’s stock worth $96,503,000 after purchasing an additional 2,564,008 shares during the last quarter. State Street Corp raised its stake in shares of Global Blood Therapeutics by 217.9% in the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock worth $58,479,000 after purchasing an additional 1,465,595 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Global Blood Therapeutics in the second quarter worth approximately $26,919,000. Vanguard Group Inc. raised its stake in shares of Global Blood Therapeutics by 40.1% in the first quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock worth $93,451,000 after purchasing an additional 726,366 shares during the last quarter. Finally, PDT Partners LLC purchased a new stake in shares of Global Blood Therapeutics in the second quarter worth approximately $7,702,000. 86.22% of the stock is owned by hedge funds and other institutional investors.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.